ALXO

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in four upcoming investor conferences.

Credit Suisse 31st Annual Healthcare ConferenceFormat: Formal presentationDate: Wednesday, November 9Time: 9:50 AM Pacific Time/ 12:50 PM Eastern TimeLocation: Rancho Palos Verdes, CAWebcast link: Available here

Stifel 2022 Healthcare ConferenceFormat: Fireside chat with analyst, Bradley CaninoDate: Tuesday, November 15Time: 3:00 PM Eastern TimeLocation: New York, NYWebcast link: Available here

Jefferies London Healthcare ConferenceFormat: Fireside chat with analyst, Michael YeeDate: Thursday, November 17Time: 2:40 PM Greenwich Mean Time/ 9:40 AM Eastern TimeLocation: London, UKWebcast link: Available here

Piper Sandler 34th Annual Healthcare ConferenceFormat: Fireside chat with analyst, Chris RaymondDate: Tuesday, November 29Time: 9:00 AM Eastern TimeLocation: New York, NYWebcast link: Will be made available on ALX Oncology website

A live webcast of the presentation and fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the presentation and fireside chat dates.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.

Investor Contact:

Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com

Argot Partners
(212) 600-1902
alxoncology@argotpartners.com

Media Contact:

Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com